Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia
This study aimed to assess the prognostic influences of Wilms’ tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML) among Egyptian patients. Exons 7 of WT1 was screened for mutations in samples from 82 CN-AML patients out of 203 newly diagnosed AML patients,...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2014-08-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://mjhid.org/index.php/mjhid/article/view/1725 |
id |
doaj-ec252801d321428d84738d85f3c8d696 |
---|---|
record_format |
Article |
spelling |
doaj-ec252801d321428d84738d85f3c8d6962020-11-25T03:27:55ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemiaSALAHA AREF0Solafa El SharawyEmaad AzmyMohamed SabryDalia Abdel RaoufMansoura Faculty of Medicine This study aimed to assess the prognostic influences of Wilms’ tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML) among Egyptian patients. Exons 7 of WT1 was screened for mutations in samples from 82 CN-AML patients out of 203 newly diagnosed AML patients, using a high-resolution capillary electrophoresis. Seven out of 82 AML patients (8.3%) harbored WT1 mutations. There was no significant difference between the mutant WT1 and wild type AML patients as regard age, sex, French-American-British subtypes and the prevalence of success of induction remission therapy (P < 0.5). AML patients with mutant WT1 had shorter overall survival (OS) as compared to those patients with wild WT1 (HR= 1.38; 95%; CI 4.79 - 6.86; P = 0.004). In conclusion, CN-AML patients with WT1 gene mutation have poor clinical outcome. We recommend testing the WT1 mutations as part of molecularly based risk assessment and risk-adapted treatment stratification of patients with CN-AML. https://mjhid.org/index.php/mjhid/article/view/1725Leukemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
SALAHA AREF Solafa El Sharawy Emaad Azmy Mohamed Sabry Dalia Abdel Raouf |
spellingShingle |
SALAHA AREF Solafa El Sharawy Emaad Azmy Mohamed Sabry Dalia Abdel Raouf Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia Mediterranean Journal of Hematology and Infectious Diseases Leukemia |
author_facet |
SALAHA AREF Solafa El Sharawy Emaad Azmy Mohamed Sabry Dalia Abdel Raouf |
author_sort |
SALAHA AREF |
title |
Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia |
title_short |
Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia |
title_full |
Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia |
title_fullStr |
Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia |
title_full_unstemmed |
Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia |
title_sort |
prognostic relevance of wilms tumor 1 (wt1) gene mutation in-patient with acute myeloid leukemia |
publisher |
PAGEPress Publications |
series |
Mediterranean Journal of Hematology and Infectious Diseases |
issn |
2035-3006 |
publishDate |
2014-08-01 |
description |
This study aimed to assess the prognostic influences of Wilms’ tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML) among Egyptian patients.
Exons 7 of WT1 was screened for mutations in samples from 82 CN-AML patients out of 203 newly diagnosed AML patients, using a high-resolution capillary electrophoresis.
Seven out of 82 AML patients (8.3%) harbored WT1 mutations. There was no significant difference between the mutant WT1 and wild type AML patients as regard age, sex, French-American-British subtypes and the prevalence of success of induction remission therapy (P < 0.5). AML patients with mutant WT1 had shorter overall survival (OS) as compared to those patients with wild WT1 (HR= 1.38; 95%; CI 4.79 - 6.86; P = 0.004). In conclusion, CN-AML patients with WT1 gene mutation have poor clinical outcome. We recommend testing the WT1 mutations as part of molecularly based risk assessment and risk-adapted treatment stratification of patients with CN-AML.
|
topic |
Leukemia |
url |
https://mjhid.org/index.php/mjhid/article/view/1725 |
work_keys_str_mv |
AT salahaaref prognosticrelevanceofwilmstumor1wt1genemutationinpatientwithacutemyeloidleukemia AT solafaelsharawy prognosticrelevanceofwilmstumor1wt1genemutationinpatientwithacutemyeloidleukemia AT emaadazmy prognosticrelevanceofwilmstumor1wt1genemutationinpatientwithacutemyeloidleukemia AT mohamedsabry prognosticrelevanceofwilmstumor1wt1genemutationinpatientwithacutemyeloidleukemia AT daliaabdelraouf prognosticrelevanceofwilmstumor1wt1genemutationinpatientwithacutemyeloidleukemia |
_version_ |
1724586388189347840 |